busulfan has been researched along with Bone Cancer in 26 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report a prospective Phase II study of efficacy and toxicity for oral treosulfan in advanced Ewing sarcoma." | 9.20 | A phase II study to determine the efficacy and safety of oral treosulfan in patients with advanced pre-treated Ewing sarcoma ISRCTN11631773. ( Forsyth, S; Michelagnoli, M; Whelan, J, 2015) |
| "Dose-intensive chemotherapy with vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide is more effective, less toxic, and shorter in duration for all stages of newly diagnosed Ewing sarcoma than vincristine, ifosfamide, doxorubicin, and etoposide induction and should now be the standard of care for Ewing sarcoma." | 5.51 | Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial. ( Brennan, B; Fenwick, N; Gaspar, N; Gelderblom, H; Kirton, L; Laurence, V; Marec-Bérard, P; Martín-Broto, J; Moroz, V; Owens, C; Sastre, A; Strauss, S; Wheatley, K; Whelan, J, 2022) |
| "Busulfan has been widely used to treat CML." | 5.40 | Busulfan inhibits growth of human osteosarcoma through miR-200 family microRNAs in vitro and in vivo. ( Li, F; Liu, Y; Mei, Q; Quan, H; Xu, H, 2014) |
| "Radiation myelopathy is a rare, devastating, late effect of radiotherapy to the spinal cord." | 5.33 | Fatal radiation myelopathy after high-dose busulfan and melphalan chemotherapy and radiotherapy for Ewing's sarcoma: a review of the literature and implications for practice. ( Cassoni, AM; Galloway, MJ; Rees, JH; Seddon, BM; Whelan, JS, 2005) |
| "We report a prospective Phase II study of efficacy and toxicity for oral treosulfan in advanced Ewing sarcoma." | 5.20 | A phase II study to determine the efficacy and safety of oral treosulfan in patients with advanced pre-treated Ewing sarcoma ISRCTN11631773. ( Forsyth, S; Michelagnoli, M; Whelan, J, 2015) |
| "Patients aged ≤40 years with nonmetastatic Ewing sarcoma (ES) received vincristine (V), doxorubicin (A), cyclofosfamide (C), actinomycin (Ac), ifosfamide (I) and etoposide (E) (VACAc-IE regimen) as induction chemotherapy." | 5.15 | Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol. ( Alberghini, M; Alvegard, TA; Bacci, G; Barbieri, E; Brach Del Prever, A; Capanna, R; Carli, M; Fagioli, F; Ferrari, S; Gandola, L; Luksch, R; Mapelli, S; Mercuri, M; Picci, P; Prete, A; Smeland, S; Sundby Hall, K; Tamburini, A; Tienghi, A; Wiebe, T, 2011) |
| "To improve the prognosis for patients with metastatic Ewing sarcoma/primitive neuroectodermal tumors (ES/PNET) using conventional chemotherapy and consolidation high-dose chemotherapy (HDCT) containing busulfan and melphalan." | 5.12 | Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Société Française des Cancers de l'Enfant. ( Desfachelles, AS; Lejars, O; Michon, J; Oberlin, O; Philip, T; Plantaz, D; Plouvier, E; Rey, A; Rubie, H; Schmitt, C; Terrier, P, 2006) |
| "Post-relapse survival (PRS) was evaluated in patients with Ewing sarcoma (EWS) enrolled in chemotherapy protocols based on the use of high-dose chemotherapy with busulfan and melfalan (HDT) as a first-line consolidation treatment in high-risk patients." | 3.81 | Post-relapse survival in patients with Ewing sarcoma. ( Abate, ME; Brach del Prever, A; Cammelli, S; DiGirolamo, S; Eriksson, M; Fagioli, F; Ferrari, S; Hall, KS; Luksch, R; Paioli, A; Podda, M; Prete, A; Tamburini, A; Tienghi, A, 2015) |
| "To evaluate the potential of diffusion-weighted imaging (DWI) for monitoring dose-dependent tumor response in a mouse-xenograft model of Ewing sarcoma after administration of treosulfan in different dosages." | 3.75 | Diffusion-weighted imaging as predictor of therapy response in an animal model of Ewing sarcoma. ( Elverfeldt, DV; Juettner, E; Kontny, U; Reichardt, W; Uhl, M, 2009) |
| " As little data are available about the in-vitro toxicity of busulfan and treosulfan especially on pediatric tumor cell lines, we compared the cytotoxicity of treosulfan and busulfan on four Ewing tumor, four neuroblastoma, two osteosarcoma and two leukemia cell lines in vitro." | 3.73 | Cytotoxicity of treosulfan and busulfan on pediatric tumor cell lines. ( Boos, J; Bremer, A; Dirksen, U; Jürgens, H; Lanvers-Kaminsky, C, 2006) |
| "Busulfan has been widely used to treat CML." | 1.40 | Busulfan inhibits growth of human osteosarcoma through miR-200 family microRNAs in vitro and in vivo. ( Li, F; Liu, Y; Mei, Q; Quan, H; Xu, H, 2014) |
| "Radiation myelopathy is a rare, devastating, late effect of radiotherapy to the spinal cord." | 1.33 | Fatal radiation myelopathy after high-dose busulfan and melphalan chemotherapy and radiotherapy for Ewing's sarcoma: a review of the literature and implications for practice. ( Cassoni, AM; Galloway, MJ; Rees, JH; Seddon, BM; Whelan, JS, 2005) |
| "Eighteen patients with poor risk Ewing's sarcoma (including 11 patients with metastatic disease at presentation) received consolidation therapy of busulphan and melphalan with autologous stem cell rescue." | 1.30 | High-dose busulphan/melphalan with autologous stem cell rescue in Ewing's sarcoma. ( Ashley, S; Atra, A; Calvagna, V; Pinkerton, CR; Shankar, AG; Shepherd, V; Souhami, RL; Whelan, JS, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (7.69) | 18.7374 |
| 1990's | 3 (11.54) | 18.2507 |
| 2000's | 9 (34.62) | 29.6817 |
| 2010's | 8 (30.77) | 24.3611 |
| 2020's | 4 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Cohen, IJ | 1 |
| Ash, S | 1 |
| Brennan, B | 3 |
| Kirton, L | 2 |
| Marec-Bérard, P | 3 |
| Gaspar, N | 3 |
| Laurence, V | 4 |
| Martín-Broto, J | 3 |
| Sastre, A | 3 |
| Gelderblom, H | 3 |
| Owens, C | 3 |
| Fenwick, N | 3 |
| Strauss, S | 3 |
| Moroz, V | 3 |
| Whelan, J | 4 |
| Wheatley, K | 3 |
| Anderton, J | 1 |
| Kaiser, S | 1 |
| Fernández-Pinto, M | 1 |
| Evans, A | 1 |
| Uemura, S | 1 |
| Mori, T | 1 |
| Ishiko, S | 1 |
| Takafuji, S | 1 |
| Nino, N | 1 |
| Yamamoto, N | 1 |
| Hayakawa, A | 1 |
| Nishimura, N | 1 |
| Hara, H | 1 |
| Kawamoto, T | 1 |
| Akisue, T | 1 |
| Iijima, K | 1 |
| Mei, Q | 1 |
| Li, F | 1 |
| Quan, H | 1 |
| Liu, Y | 1 |
| Xu, H | 1 |
| Michelagnoli, M | 1 |
| Forsyth, S | 1 |
| Ferrari, S | 3 |
| Luksch, R | 3 |
| Hall, KS | 2 |
| Fagioli, F | 3 |
| Prete, A | 3 |
| Tamburini, A | 3 |
| Tienghi, A | 3 |
| DiGirolamo, S | 1 |
| Paioli, A | 1 |
| Abate, ME | 2 |
| Podda, M | 2 |
| Cammelli, S | 1 |
| Eriksson, M | 2 |
| Brach del Prever, A | 2 |
| Reichardt, W | 1 |
| Juettner, E | 1 |
| Uhl, M | 1 |
| Elverfeldt, DV | 1 |
| Kontny, U | 1 |
| Bölling, T | 1 |
| Dirksen, U | 2 |
| Ranft, A | 1 |
| Ernst, I | 1 |
| Jürgens, H | 2 |
| Willich, N | 1 |
| Sundby Hall, K | 1 |
| Wiebe, T | 1 |
| Alvegard, TA | 1 |
| Alberghini, M | 1 |
| Gandola, L | 2 |
| Mercuri, M | 1 |
| Capanna, R | 1 |
| Mapelli, S | 1 |
| Carli, M | 1 |
| Picci, P | 2 |
| Barbieri, E | 2 |
| Bacci, G | 1 |
| Smeland, S | 2 |
| Molina, B | 1 |
| Alonso, L | 1 |
| Gonzalez-Vicent, M | 1 |
| Andion, M | 1 |
| Hernandez, C | 1 |
| Lassaletta, A | 1 |
| Cormenzana, M | 1 |
| Lopez-Ibor, B | 1 |
| Villa, M | 1 |
| Molina, J | 1 |
| Diaz, MA | 2 |
| Drabko, K | 1 |
| Raciborska, A | 1 |
| Bilska, K | 1 |
| Styczynski, J | 1 |
| Ussowicz, M | 1 |
| Choma, M | 1 |
| Wojcik, B | 1 |
| Zaucha-Prazmo, A | 1 |
| Gorczynska, E | 1 |
| Skoczen, S | 1 |
| Wozniak, W | 1 |
| Chybicka, A | 1 |
| Wysocki, M | 1 |
| Gozdzik, J | 1 |
| Kowalczyk, J | 1 |
| Ruggieri, P | 1 |
| Daolio, P | 1 |
| Lindholm, P | 1 |
| Bisogno, G | 1 |
| Grignani, G | 1 |
| Grunebaum, E | 1 |
| Daneman, A | 1 |
| Murguia-Favela, L | 1 |
| Manson, D | 1 |
| Kim, VH | 1 |
| Roifman, CM | 1 |
| Grunebaum, M | 1 |
| Pierga, JY | 1 |
| Barthier, S | 1 |
| Babinet, A | 1 |
| Alapetite, C | 1 |
| Palangié, T | 1 |
| de Pinieux, G | 1 |
| Anract, P | 1 |
| Pouillart, P | 1 |
| Seddon, BM | 1 |
| Cassoni, AM | 1 |
| Galloway, MJ | 1 |
| Rees, JH | 1 |
| Whelan, JS | 3 |
| Walther, J | 1 |
| Sivabalasingham, S | 1 |
| Plowman, PN | 1 |
| McTiernan, A | 1 |
| Driver, D | 1 |
| Michelagnoli, MP | 1 |
| Kilby, AM | 1 |
| Lanvers-Kaminsky, C | 1 |
| Bremer, A | 1 |
| Boos, J | 1 |
| Oberlin, O | 1 |
| Rey, A | 1 |
| Desfachelles, AS | 1 |
| Philip, T | 1 |
| Plantaz, D | 1 |
| Schmitt, C | 1 |
| Plouvier, E | 1 |
| Lejars, O | 1 |
| Rubie, H | 1 |
| Terrier, P | 1 |
| Michon, J | 1 |
| Juncá Piera, J | 1 |
| Durán Suárez, JR | 1 |
| Triginer Boixeda, J | 1 |
| Atra, A | 1 |
| Calvagna, V | 1 |
| Shankar, AG | 1 |
| Ashley, S | 1 |
| Shepherd, V | 1 |
| Souhami, RL | 1 |
| Pinkerton, CR | 1 |
| Yonemoto, T | 1 |
| Tatezaki, S | 1 |
| Ishii, T | 1 |
| Satoh, T | 1 |
| Vicent, MG | 1 |
| Madero, L | 1 |
| Bordigoni, P | 1 |
| Turello, R | 1 |
| Clement, L | 1 |
| Lascombes, P | 1 |
| Leheup, B | 1 |
| Galloy, MA | 1 |
| Plenat, F | 1 |
| Kredel, L | 1 |
| Tittor, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Metformin as Maintenance Therapy in Patients With Bone Sarcoma and High Risk of Relapse[NCT04758000] | Phase 2 | 67 participants (Anticipated) | Interventional | 2021-03-01 | Recruiting | ||
| Observational Study on Treatment of Skeletal Ewing Sarcoma at Diagnosis[NCT04845893] | 100 participants (Anticipated) | Observational | 2021-06-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for busulfan and Bone Cancer
| Article | Year |
|---|---|
Long-term follow up of high-dose chemotherapy with autologous stem cell rescue in adults with Ewing tumor.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2005 |
[Chemotherapy of malignant tumors].
Topics: Androgens; Antibiotics, Antineoplastic; Antineoplastic Agents; Asparaginase; Bone Neoplasms; Breast | 1975 |
7 trials available for busulfan and Bone Cancer
| Article | Year |
|---|---|
Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Bone Neoplasms; Busulfan; Cyclophosph | 2022 |
Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Bone Neoplasms; Busulfan; Cyclophosph | 2022 |
Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Bone Neoplasms; Busulfan; Cyclophosph | 2022 |
Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Bone Neoplasms; Busulfan; Cyclophosph | 2022 |
International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours - EURO EWING 2012 Protocol.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; | 2020 |
Retrospective analysis of high-dose chemotherapy followed by autologous stem cell transplantation for high-risk pediatric osteosarcoma.
Topics: Adolescent; Bone Neoplasms; Busulfan; Child; Female; Hematopoietic Stem Cell Transplantation; Humans | 2020 |
A phase II study to determine the efficacy and safety of oral treosulfan in patients with advanced pre-treated Ewing sarcoma ISRCTN11631773.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Busulfan | 2015 |
Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Busulfan; Child; | 2011 |
Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Société Française des Cancers de l'Enfant.
Topics: Adolescent; Adult; Analysis of Variance; Antineoplastic Agents, Alkylating; Antineoplastic Combined | 2006 |
High-dose busulfan/melphalan as conditioning for autologous PBPC transplantation in pediatric patients with solid tumors.
Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Agents, Alkylating; Blood Cell Count; Bone Disease | 1999 |
17 other studies available for busulfan and Bone Cancer
| Article | Year |
|---|---|
New Approaches Promise to Improve Local Ewing Sarcoma Results.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Busulfan; Disease-Free Survival; Hum | 2022 |
Busulfan inhibits growth of human osteosarcoma through miR-200 family microRNAs in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Bone Neoplasms; Busulfan; Cell Line, Tumor; C | 2014 |
Post-relapse survival in patients with Ewing sarcoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Busulfan; Child; | 2015 |
Diffusion-weighted imaging as predictor of therapy response in an animal model of Ewing sarcoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Bone Neoplasms; Busulfan; Cell Line, Tumor; Diffusion Ma | 2009 |
Radiation toxicity following busulfan/melphalan high-dose chemotherapy in the EURO-EWING-99-trial: review of GPOH data.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Busulfan; Chemotherapy, | 2009 |
High-dose busulfan and melphalan as conditioning regimen for autologous peripheral blood progenitor cell transplantation in high-risk neuroblastoma patients.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Bone Marrow Neoplasms; Bone Neoplasms; Busulfan; Chil | 2011 |
Consolidation of first-line therapy with busulphan and melphalan, and autologous stem cell rescue in children with Ewing's sarcoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Busulfan; Child; | 2012 |
Primary metastatic Ewing's family tumors: results of the Italian Sarcoma Group and Scandinavian Sarcoma Group ISG/SSG IV Study including myeloablative chemotherapy and total-lung irradiation.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neopl | 2012 |
Multiple osteochondromas following irradiation-containing conditioning in severe combined immunodeficiency.
Topics: Age Factors; Bone Marrow Transplantation; Bone Neoplasms; Busulfan; Cyclophosphamide; Humans; Infant | 2013 |
Fatal radiation myelopathy after high-dose busulfan and melphalan chemotherapy and radiotherapy for Ewing's sarcoma: a review of the literature and implications for practice.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Busulfan; Combined Modal | 2005 |
Chemotherapy and radiotherapy causing radiation myelopathy: what is to blame?
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Busulfan; Humans; Male; | 2006 |
High dose chemotherapy with bone marrow or peripheral stem cell rescue is an effective treatment option for patients with relapsed or progressive Ewing's sarcoma family of tumours.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Bone Neoplasms; Busulfa | 2006 |
Cytotoxicity of treosulfan and busulfan on pediatric tumor cell lines.
Topics: Antineoplastic Agents, Alkylating; Bone Neoplasms; Busulfan; Cell Survival; Humans; Leukemia; Neurob | 2006 |
[Osteolytic lesions in chronic myeloid leukemia. Report of three cases (author's transl)].
Topics: Adult; Aged; Bone Neoplasms; Bone Resorption; Busulfan; Female; Humans; Leukemia, Myeloid; Male; Mer | 1981 |
High-dose busulphan/melphalan with autologous stem cell rescue in Ewing's sarcoma.
Topics: Adolescent; Adult; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; | 1997 |
[High-dose chemotherapy with autologous peripheral blood stem cell transplantation (PBSCT) for refractory bone and soft tissue sarcomas].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Busulfan; Child; | 1999 |
Osteochondroma after pediatric hematopoietic stem cell transplantation: report of eight cases.
Topics: Actuarial Analysis; Acute Disease; Bone Neoplasms; Busulfan; Child; Child, Preschool; Cranial Irradi | 2002 |